CRYO-CELL INTL INC (CCEL) Stock Fundamental Analysis
NYSEARCA:CCEL - NYSE Arca - US2288951088 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to CCEL. CCEL was compared to 103 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of CCEL while its profitability can be described as average. CCEL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CCEL has reported negative net income.
CCEL had a positive operating cash flow in the past year.
Of the past 5 years CCEL 4 years were profitable.
Each year in the past 5 years CCEL had a positive operating cash flow.
1.2 Ratios
CCEL has a Return On Assets of -0.27%. This is comparable to the rest of the industry: CCEL outperforms 47.57% of its industry peers.
CCEL has a better Return On Invested Capital (7.06%) than 70.87% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CCEL is below the industry average of 9.72%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.27% | ||
| ROE | N/A | ||
| ROIC | 7.06% |
ROA(3y)-3.55%
ROA(5y)0.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.61%
ROIC(5y)11.38%
1.3 Margins
CCEL's Profit Margin has declined in the last couple of years.
CCEL has a better Operating Margin (11.93%) than 83.50% of its industry peers.
In the last couple of years the Operating Margin of CCEL has declined.
CCEL has a better Gross Margin (76.23%) than 89.32% of its industry peers.
CCEL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.93% | ||
| PM (TTM) | N/A | ||
| GM | 76.23% |
OM growth 3Y-12.93%
OM growth 5Y-12.62%
PM growth 3Y-44.14%
PM growth 5Y-29.46%
GM growth 3Y2.95%
GM growth 5Y1.88%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CCEL is destroying value.
CCEL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CCEL has been increased compared to 5 years ago.
The debt/assets ratio for CCEL has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.06, we must say that CCEL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.06, CCEL is not doing good in the industry: 76.70% of the companies in the same industry are doing better.
The Debt to FCF ratio of CCEL is 1.42, which is an excellent value as it means it would take CCEL, only 1.42 years of fcf income to pay off all of its debts.
CCEL's Debt to FCF ratio of 1.42 is amongst the best of the industry. CCEL outperforms 84.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.42 | ||
| Altman-Z | 0.06 |
ROIC/WACC0.61
WACC11.5%
2.3 Liquidity
A Current Ratio of 0.60 indicates that CCEL may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.60, CCEL is doing worse than 88.35% of the companies in the same industry.
CCEL has a Quick Ratio of 0.60. This is a bad value and indicates that CCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.57, CCEL is not doing good in the industry: 84.47% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
CCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.20%, which is quite impressive.
CCEL shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -29.04% yearly.
CCEL shows a small growth in Revenue. In the last year, the Revenue has grown by 1.10%.
CCEL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.11% yearly.
EPS 1Y (TTM)98.2%
EPS 3Y-41.85%
EPS 5Y-29.04%
EPS Q2Q%-50%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y3.46%
Revenue growth 5Y0.11%
Sales Q2Q%-0.89%
3.2 Future
Based on estimates for the next years, CCEL will show a very negative growth in Earnings Per Share. The EPS will decrease by -68.82% on average per year.
The Revenue is expected to grow by 0.77% on average over the next years.
EPS Next Y-304%
EPS Next 2Y-68.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.59%
Revenue Next 2Y0.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCEL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
CCEL's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CCEL is cheaper than 78.64% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CCEL indicates a rather cheap valuation: CCEL is cheaper than 90.29% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.68 | ||
| EV/EBITDA | 8.01 |
4.3 Compensation for Growth
A cheap valuation may be justified as CCEL's earnings are expected to decrease with -68.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.82%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 17.99%, CCEL is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.61, CCEL pays a better dividend. On top of this CCEL pays more dividend than 100.00% of the companies listed in the same industry.
CCEL's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 17.99% |
5.2 History
CCEL has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
The earnings of CCEL are negative and hence is the payout ratio. CCEL will probably not be able to sustain this dividend level.
DP-3067.58%
EPS Next 2Y-68.82%
EPS Next 3YN/A
NYSEARCA:CCEL (7/28/2025, 8:13:24 PM)
4.92
-0.08 (-1.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners7.68%
Inst Owner Change0%
Ins Owners40.17%
Ins Owner Change0.38%
Market Cap39.66M
Analysts82.86
Price Target8.67 (76.22%)
Short Float %0.18%
Short Ratio0.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 17.99% |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP-3067.58%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.33%
Max Revenue beat(2)-0.9%
Revenue beat(4)0
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-3.33%
Max Revenue beat(4)-0.9%
Revenue beat(8)0
Avg Revenue beat(8)-1.76%
Revenue beat(12)3
Avg Revenue beat(12)-0.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-350%
EPS NQ rev (3m)-350%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-2.14%
Revenue NQ rev (3m)-2.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.24 | ||
| P/FCF | 6.68 | ||
| P/OCF | 6.34 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.01 |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)0.74
FCFY14.97%
OCF(TTM)0.78
OCFY15.77%
SpS3.97
BVpS-1.93
TBVpS-2.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.27% | ||
| ROE | N/A | ||
| ROCE | 8.94% | ||
| ROIC | 7.06% | ||
| ROICexc | 7.88% | ||
| ROICexgc | 8.51% | ||
| OM | 11.93% | ||
| PM (TTM) | N/A | ||
| GM | 76.23% | ||
| FCFM | 18.56% |
ROA(3y)-3.55%
ROA(5y)0.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.61%
ROIC(5y)11.38%
ROICexc(3y)7.98%
ROICexc(5y)14.72%
ROICexgc(3y)8.63%
ROICexgc(5y)16.85%
ROCE(3y)9.64%
ROCE(5y)14.41%
ROICexcg growth 3Y-17.95%
ROICexcg growth 5Y-25.17%
ROICexc growth 3Y-16.74%
ROICexc growth 5Y-23.68%
OM growth 3Y-12.93%
OM growth 5Y-12.62%
PM growth 3Y-44.14%
PM growth 5Y-29.46%
GM growth 3Y2.95%
GM growth 5Y1.88%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.42 | ||
| Debt/EBITDA | 1.65 | ||
| Cap/Depr | 26.99% | ||
| Cap/Sales | 1% | ||
| Interest Coverage | 1.89 | ||
| Cash Conversion | 125.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 0.06 |
F-Score7
WACC11.5%
ROIC/WACC0.61
Cap/Depr(3y)548.95%
Cap/Depr(5y)370.25%
Cap/Sales(3y)23.15%
Cap/Sales(5y)15.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.2%
EPS 3Y-41.85%
EPS 5Y-29.04%
EPS Q2Q%-50%
EPS Next Y-304%
EPS Next 2Y-68.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.1%
Revenue growth 3Y3.46%
Revenue growth 5Y0.11%
Sales Q2Q%-0.89%
Revenue Next Year0.59%
Revenue Next 2Y0.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.29%
EBIT growth 3Y-9.92%
EBIT growth 5Y-12.52%
EBIT Next Year-1.89%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y238.22%
FCF growth 3Y-15.98%
FCF growth 5Y-8.62%
OCF growth 1Y-28.52%
OCF growth 3Y-8.81%
OCF growth 5Y-1.01%